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ABSTRACT
Reduced-intensity conditioning regimens allow application of allogeneic stem cell transplantation to greater
numbers of patients with myeloma by reducing transplantation-related mortality. We prospectively evaluated
the role of an approach incorporating in vivo T-cell depletion and subsequent adjuvant donor lymphocyte
infusions (DLIs) as part of front-line therapy for chemotherapy-sensitive multiple myeloma. Twenty patients
with HLA-matched related (n  12) or unrelated (n  8) donors entered the study. None had previously
undergone autologous transplantation. Acute graft-versus-host disease (GVHD) following transplantation was
minimal (3 grade II and no grade III or IV). Nonrelapse mortality rate was relatively low (15%) compared with
conventional myeloablative allogeneic transplantation series, although it remained significantly higher than in
the autologous setting. Disease responses by 6 months posttransplantation were modest (2 in complete
remission, 4 in partial remission, 2 were minimally responsive, 6 had no change, 3 had progressive disease, and
3 were not evaluable). Fourteen patients received escalating-dose DLI for residual/progressive disease. Three
developed acute GVHD and 2 developed limited chronic GVHD. Seven demonstrated further disease re-
sponses, which appeared to be more common in those developing GVHD (5 of 5 versus 2 of 9; P  .02). All
responses were associated with conversion from mixed to full donor T-cell chimerism. Response durations
were disappointing (5 <12 months) and progression often occurred despite persisting full donor chimerism.
Two-year estimated overall survival and current progression-free survival rates (intention to treat with DLI
from 6 months) were 71% and 30%, respectively. The current approach incorporating T-cell depletion appears
excessively immunosuppressive despite attempts to restore immune function with DLI. Dose escalation failed
to allow convincing dissociation of graft-versus-myeloma from GVHD. Attempts to hasten immune reconsti-
tution and to focus and amplify appropriate components of allogeneic T-cell responses will be required to
increase complete remission rates and response durations.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Multiple myeloma (MM) is an ultimately chemo-
therapy-refractory malignancy in which the role of
standard allogeneic bone marrow transplantation re-
mains controversial, most notably because of the high
incidence of associated NRM (nonrelapse mortality).
The older median age of patients with the disease
combined with high incidences of both graft-versus-
host disease (GVHD) and infective pathologies are all
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contributing factors [1]. Despite improvements in
supportive care, few studies have reported NRM rates
of 30% in patients who underwent transplantation
for MM [2-5]. Thus, even in the younger patient
group, strategies aimed at further reducing NRM are
warranted.
The graft-versus-malignancy effect that has been
demonstrated in patients with myeloma undergoing
allogeneic bone marrow transplantation has the po-
tential to consolidate the temporary and often incom-
plete responses achievable with even myeloablative
doses of chemotherapy. The realization that the allo-
geneic graft can mediate an antitumor effect coupled
with the observation that engraftment can be achieved
without myeloablation have led to an exploration of
the use of reduced-intensity conditioning regimens to
decrease NRM [6-8]. However, the overall role and
timing of reduced-intensity stem cell transplantation
(RIT) within current treatment strategies for the man-
agement of MM have yet to be deﬁned. In particular,
initial application has generally been in patients with
advanced disease. In these cases, it appears that incor-
poration of a preceding autograft procedure may offer
the best chance of disease control prior to reduced-
intensity approaches based on minimally myelosup-
pressive conditioning. It is currently unclear whether
the inclusion of an autograft is necessary in those with
chemotherapy-sensitive disease, particularly if treat-
ment is part of front-line therapy and includes a more
myelosuppressive conditioning regimen offering
greater antitumor activity. We explored the use of a
reduced-intensity conditioning regimen containing
alemtuzumab as part of a front-line treatment proto-
col in patients with chemotherapy-sensitive MM who
had not received high-dose therapy and an autologous
stem cell transplant. This regimen has been demon-
strated to result in durable engraftment with a low
incidence of GVHD both in the matched sibling and
matched unrelated donor setting [9,10]. The attrac-
tion of this immunological approach in MM is based
on reports of the efﬁcacy of donor lymphocyte infus-
tions (DLIs) to treat disease relapse after allografting
[11,12], although preliminary evidence suggests that
higher doses may be required than in chronic myelog-
enous leukemia (CML). Experience in the treatment
of CML suggests that the use of DLI in the setting of
minimal disease (ie, cytogenetic relapse) may be asso-
ciated with increased response rates and reduced tox-
icity, perhaps in part because lower doses of DLI are
required to attain disease control [13]. Larger doses of
DLI may be administered at later time points follow-
ing transplantation with a lower risk of toxicity than
the same doses at early time points [14-16], but little
is known regarding the optimal dose and timing of
DLI following allogeneic transplantation and how this
may vary according to disease diagnosis, conditioning
regimen, and donor type. In vivo graft T-cell deple-
tion secondary to persistent alemtuzumab [17] poten-
tially compromises graft-versus-myeloma (GVM) ac-
tivity and adjuvant unselected DLI was planned in a
dose-escalating protocol from 12 months posttrans-
plantation. However, disease progression occurring
between 6 and 12 months posttransplantation in the
ﬁrst 2 patients led to a protocol amendment with
adjuvant DLI subsequently administered from 6
months posttransplantation.
PATIENTS AND METHODS
Eligibility Criteria
Patients with chemotherapy-sensitive MM with
either a fully HLA-matched sibling donor or a
matched unrelated donor (aged 35 to 60 years) were
eligible. Patients having previously undergone autol-
ogous bone marrow transplantation were ineligible.
Patients were excluded if left ventricular ejection frac-
tion was 40%, creatinine clearance was 40 mL/
min, bilirubin was greater than 34 mol/L, or liver
transaminases were greater than 3 times the upper
limit of normal.
Patient Characteristics
Twenty patients entered the study. Eleven had a
matched sibling, 1 had a fully HLA-matched cousin,
and 8 had matched unrelated donors (Table 1). Four
of the unrelated donors had some degree of mismatch
at HLA class I and/or class II alleles (molecular typ-
ing). These included 2 cases of bidirectional 1 antigen
class C mismatch, 1 case of bidirectional 1 antigen
DQB1 mismatch, and 1 case of bidirectional 2 antigen
class C and 1 antigen DQB1 mismatch. The majority
(60%) had Durie-Salmon Stage III disease at diagno-
sis. Initial cytoreduction was with either vincristine,
doxorubicin, dexamethasone [18] or cyclophospha-
mide, vincristine, doxorubicin, methylprednisolone
[19]. Salvage for those with unresponsive or minimally
responsive disease (n  5) was with etoposide, meth-
ylpredisolone, cytarabine, cisplatin [20], or dexameth-
asone, cyclophosphamide, etoposide [21] (omitting
cisplatin in view of impaired renal function), or inter-
mediate-dose cyclophosphamide (4 g/m2 intrave-
nously). Treatment was continued until maximum re-
sponse (median, 6 cycles of chemotherapy; range: 4 to
8) and RIT performed within 4 months of the last
cycle of chemotherapy (Table 1). The patients ranged
in age from 34 to 58 years (median, 47 years). At the
time of allograft, 1 patient was in complete remission
(CR), 18 in partial remission (PR), and 1 had mini-
mally responsive disease. The median follow-up
among those alive (n  13) is 693 days (range: 234 to
899 days).
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Study Design
The institutional Ethics Committee approved the
study protocol. Patients and donors gave written in-
formed consent. The conditioning regimen consisted
of intravenous infusion of alemtuzumab (humanized
anti-CD52) monoclonal antibody 20 mg/d from day
-8 to -4 (total of 5 doses), ﬂudarabine 30 mg/m2/d
from day -7 to -3 (total of 5 doses), and melphalan 140
mg/m2 on day -2. Cyclosporine A was administered as
an intravenous infusion over 6 hours at 3 mg/kg/d
starting on day -1, with a target level of 300 ng/mL.
On day 0, patients received granulocyte colony-stim-
ulating factor–mobilized unmanipulated allogeneic
peripheral blood stem cell grafts from their HLA-
matched siblings/cousin (n  11/1) or unrelated do-
nors (n  2), or unmanipulated bone marrow grafts in
the case of the majority of matched unrelated donor
allografts (n 6). Targeted stem cell dose was 4 106
CD34 cells/kg.
Antiviral prophylaxis consisted of intravenous aci-
clovir (250 mg/m2/d) until engraftment, converting to
oral aciclovir (200 mg twice daily) prior to discharge.
Weekly surveillance for cytomegalovirus (CMV) in-
fection was performed using PCR for CMV DNA on
either whole blood or plasma. Those testing positive
on 2 consecutive weeks were treated with intravenous
ganciclovir or foscarnet according to institutional
guidelines. Oral cotrimoxazole (960 mg twice daily)
was administered from day -8 to day -1 as prophylaxis
against Pneumocystis carinii infection. Nebulized pent-
amidine was given prior to discharge and then
monthly until cytopenia no longer precluded prophy-
laxis with cotrimoxazole (960 mg twice daily on 3 days
per week). Patients at high risk of fungal infection
received intravenous itraconazole until discharge. Fe-
brile neutropenic patients received broad-spectrum
antibiotics according to institutional guidelines.
In the absence of GVHD, cyclosporine A was
tapered from 3 months posttransplantation. Patients
who had residual disease or mixed chimerism at 6
months posttransplantation were eligible to receive
DLI if there was no evidence of active GVHD. Esca-
lating doses of CD3 lymphocytes were administered
starting at a dose of 1  106 T cells/kg. Increasing
doses were administered at 3 monthly intervals (3 
106, 1  107, 3  107, 1  108 T cells/kg) in the
absence of development of GVHD if either residual
disease or mixed chimerism persisted. Lineage-spe-
ciﬁc chimerism (in T-cell, B-cell, and myeloid lin-
eages) was assessed by means of PCR analysis of in-
formative minisatellite regions (short tandem repeat
loci) as previously described [9]. In some cases, lym-
phopenia precluded T- and B-cell chimerism analysis.
Study End Points
The primary end points of the study were to eval-
uate engraftment, toxicity, NRM, incidence of
GVHD, lineage-speciﬁc chimerism, and toxicity of
Table 1. Patient Characteristics
Patient
No. Age/Sex
Disease
Phenotype
Durie-
Salmon
Stage
No. of Prior
Standard
Chemotherapies*
Response
Status at
RIT
Donor and
Graft
Characteristics
01 43/F Light chain  III 6 PR Stem cell-sibling
02 46/F Nonsecretory  III 5 PR Stem cell-sibling
03 42/F IgG  III 6 PR Marrow-MUD
04 47/M IgG  III 7  1 PR Marrow-MUD
05 34/M IgG  III 4  1 MR Marrow-MUD
06 44/M IgG  II 6  1 PR Stem cell-sibling
07 55/M IgG  III 4  1† PR Stem cell-sibling
08 47/M IgA  III 5 PR Marrow-MUD
09 53/M IgG III 6 PR Stem cell-sibling
10 58/F IgG II 6 PR Stem cell-sibling
11 50/M IgA  III 7  1‡ PR Stem cell-sibling
12 46/M IgG II 4 PR Stem cell-sibling
13 52/M IgG  II 7 PR Marrow-MUD
14 52/M IgG  III 7 PR Stem cell-sibling
15 47/M IgG  II 4 PR Marrow-MUD
16 46/M Light chain  II 5 CR Stem cell-cousin
17 51/M IgG  III 5 PR Stem cell-sibling
18 51/M IgA II 5 PR Stem cell-sibling
19 48/M Light chain  II 6 PR Stem cell-MUD
20 47/M IgG III 5 PR Stem cell-MUD
F indicates female; M, male; Ig, immunoglobulin; PR, partial remission; MR, minimal response; CR, complete remission.
*Indicates no. of cycles of ﬁrst-line chemotherapy (VAD/CVAMP) plus number of cycles of salvage chemotherapy (ESHAP unless
otherwise indicated).
†Salvaged with DCE.
‡Salvaged with cyclophosphamide.
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adjuvant DLI. Acute GVHD was assessed according
to the International Bone Marrow Transplant Regis-
try [IBMTR] criteria. Cases of acute and chronic
GHVD following DLI were graded according to con-
sensus criteria. Disease response was the major sec-
ondary end point. Response criteria were assessed
according to EBMT/IBMTR/ABMTR criteria [22].
Pretransplantation restaging investigations were used
as the reference point for subsequent evaluations of
disease response secondary to the transplantation pro-
cedure, and pre-DLI levels were used as the reference
point for evaluation of DLI efﬁcacy. Complete remis-
sion required normal bone marrow examination (in-
cluding immunoglobulin light-chain immunostaining)
along with disappearance of serum/urinary monoclo-
nal protein on immunoﬁxation. Partial remission in-
dicated 50% reduction in serum paraprotein or
90% reduction in Bence Jones proteinuria. Minimal
response required a 25% to 49% reduction in serum
or a 50% to 89% reduction in urinary monoclonal
protein, and progressive disease required the reap-
pearance of serum and/or urinary monoclonal protein
in patients in CR, or a25% increase in serum and/or
urinary monoclonal protein from the lowest value
observed from patients in PR, or the development of
extramedullary disease, new lytic lesions, or hypercal-
caemia. No change indicated those cases not meeting
the criteria for minimal response or disease progres-
sion. In the case of non-secretory myeloma, PR indi-
cated 50%, and minimal response a 25% to 49%
reduction in bone marrow plasmacytosis on trephine
biopsy.
Statistical Methods
Actuarial curves were estimated according to the
Kaplan-Meier method. Overall survival was measured
from transplantation until death from any cause. Pa-
tients still alive at the time of analysis were censored at
the last follow-up date. NRM was determined from
the date of transplantation until the date of death
related to transplantation. Patients who died from
other causes were censored at the time of death. Cur-
rent progression-free survival was measured from
transplantation until progression or death from any
cause. Patients who had responded to DLI without
subsequent progression at the time of analysis and
those who remained alive and progression-free since
the time of transplantation were censored at the last
follow-up date. Fisher exact test for categorical data was
used to compare the association of GVHD and disease
response from a 2  2 table as detailed in the text.
RESULTS
Engraftment and Early Toxicity
Nineteen patients achieved sustained engraftment
(Table 2). One failed to regenerate peripheral counts
by day 28 following RIT (patient 18). Bone marrow
examination revealed a profoundly hypocellular mar-
row populated by small numbers of lymphocytes and
plasma cells. Chimerism analysis of peripheral blood
mononuclear cells showed full donor chimerism and,
therefore, the patient received further donor periph-
eral blood stem cells (3.4  106 CD34 cells/kg)
without additional conditioning on day 35. Neutro-
phil engraftment (0.5  109/L) occurred on day 45
and platelet engraftment (20  109/L) occurred on
day 52. Three patients developed acute grade II to IV
GVHD (3 had grade II, none had grade III or grade
IV) following RIT (Table 2), which responded to
topical steroids in all cases. One patient subsequently
developed limited chronic GVHD. None remained
on treatment at 6 months posttransplantation. Three
patients died from early transplantation-related com-
plications (1 had progressive respiratory aspergillus
infection, 1 had systemic adenovirus infection, and 1
had rapidly progressive pneumonitis of uncertain ae-
tiology). The actuarial 100-day and 24-month NRM
rate was 15% (Figure 1).
Infective Complications
Viral infections were common (Table 2). All 10
CMV-seropositive recipients had at least 1 episode of
CMV reactivation requiring treatment. Those with
CMV-seronegative donors had reactivations over a
particularly prolonged period (with 2 to 4 episodes of
reactivation each). There was 1 case of successfully
treated CMV interstitial pneumonitis (diagnosed on
radiological appearances and a positive detection of
early antigen ﬂuorescent foci test on bronchoalveolar
lavage). Another patient died from rapidly progressive
pneumonitis while being treated for CMV reactiva-
tion (postmortem declined). Eight patients developed
Table 2. Infective Complications
Pathogen Serostatus No. of Cases
CMV Negative/negative 0/7
Negative/positive 1/3
Positive/negative 3/3
Positive/positive 7/7†
Systemic adenovirus 2
Parainfluenza 3 virus 4
Respiratory syncitial virus 1
Influenza A virus 1
Varicella zoster virus 2
Herpes simplex virus 2
Invasive aspergillosis 2
Tuberculosis 1
Human herpes virus 7:
transverse myelitis 1
*Infection documented using PCR surveillance for CMV DNA.
†Includes 1 case of CMV interstitial pneumonitis and 1 case of
rapidly progressive fatal pneumonitis (CMV PCR positive, post
mortem declined).
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respiratory viral infections (positive immunoﬂoures-
cence tests on nasopharyngeal aspirates), and 2 pa-
tients had systemic adenoviral infections (positive
PCR tests on serum following isolation of virus from
respiratory and gastrointestinal systems). Two pa-
tients developed shingles shortly after discontinuing
aciclovir prophylaxis.
Chimerism Analysis
All 12 patients evaluated at 1 month after RIT
were full donor chimeras in all lineages tested (data
not shown). None of the 16 patients evaluated at 6
months posttransplantation maintained full donor he-
matopoiesis at all time points (Table 3). By 3 months
after RIT, mixed chimerism was demonstrable in 7 of
11 in the T-cell lineage but only 1 of 13 in the myeloid
lineage. By 6 months, 14 of 15 were mixed chimeras in
the T-cell lineage and 5 in the myeloid lineage (Table
3). The only patient with full donor chimerism in the
T-cell lineage at 6 months converted to a mixed pat-
tern by 12 months posttransplantation.
Response to RIT
Seventeen patients are evaluable for disease re-
sponse at 6 months posttransplantation prior to insti-
tution of adjuvant DLI (Table 4). The patient in CR
prior to RIT remained in CR. The patient with min-
imal response had some reduction in tumor mass but
had not attained a PR (paraprotein reduced from 22
g/L to 12 g/L, bone marrow 5% plasmacytosis).
Three of those patients who underwent transplanta-
tion in PR developed progressive disease, 1 achieved a
minimal response, 6 had no change, and 4 had a
further80% reduction in paraprotein. One achieved
a CR; this was the patient who received further donor
stem cells 35 days following RIT with subsequent
development of acute followed by chronic GVHD.
Response to DLI
The initial protocol planned for administration of
escalating doses of DLI from 12 months after RIT.
The ﬁrst 2 patients entered into the trial developed
progressive disease between 6 and 12 months after
RIT. Both failed to respond to doses of up to 1  107
and 3  106 CD3 T cells, respectively. Neither
developed GVHD and both died from progressive
disease despite salvage chemotherapy (Table 5). Sub-
sequently, patients were considered candidates for
DLI from 6 months after RIT if there was evidence of
residual disease or mixed chimerism. Eleven patients
have received DLI according to this protocol amend-
ment (Table 5). Of the other 7 patients, 3 died prior to
6 months, 1 achieved CR, and 1 developed GVHD
after RIT, had an unrelated donor, and was deemed
ineligible to receive DLI. In 1 case, the unrelated
donor was withdrawn from the transplant registry.
One patient achieved a near CR (paraprotein detect-
able but too small to quantify, bone marrow 1% poly-
typic plasma cells) by 6 months after RIT, and DLI
was not administered until day 544 (physician prefer-
ence).
Three patients developed acute GVHD (1 had
grade II, 2 had grade IV [both liver stage 3 and skin
stage 2]) (Table 5). All 3 had a disease response (PR),
although 2 died on day 303 and day 467, respectively,
secondary to infective complications (1 with further
disease progression). Two patients developed limited
chronic GVHD and both had a disease response (1CR
and 1PR). Nine patients have not developed GVHD
with current follow-up despite 3 patients receiving
Figure 1. Survival probabilities according to Kaplan-Meier curves:
(a) overall survival, (b) NRM, (c) current progression-free survival.
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escalating doses of T cells up to 1  108/kg. Six have
progressive disease (2 following an initial PR), and 3
have shown no change. Thus, overall 5 of 5 evaluable
patients who developed GVHD achieved PR/CR
compared with 2 of 9 without GVHD (P .02; Fisher
exact test) (Table 5).
Actuarial 24-month overall survival is 71% for the
group treated on the amended protocol with the in-
tention to treat with DLI from 6 months posttrans-
plantation (n  18) (Figure 1). Actuarial 24-month
progression-free survival and current progression-free
survival rates are 25% and 30%, respectively (Figure
1).
Chimerism after DLI
Eleven of the 14 patients who received DLI are
evaluable for changes in lineage-speciﬁc chimerism
status (Table 6). T-cell chimerism switched from a
mixed pattern to full donor pattern in 10 of 11 cases.
In the majority (n  7), this occurred following the
initial T-cell dose (1  106/kg in 6 patients and 1 
107/kg in 1 patient). One patient in whom no infor-
mative primers were identiﬁed had a reduction in
amount of recipient hematopoiesis assessed by ﬂuo-
rescent in situ hybridization for the presence of X/Y
chromosomes from 28% to 3%.
DISCUSSION
Mortality rates associated with conventional my-
eloablative transplantation for MM have decreased in
the last 10 years because of advances in supportive care
and a trend toward transplantation earlier in the dis-
ease course. Despite this, NRM rates still approach
30% in most series, even in the fully HLA-matched
sibling donor setting [4,5]. Thus the NRM in the
current series (15%) compares favorably, particularly
given the inclusion of 8 patients with unrelated donors
(4 with some degree of mismatch). This is largely
Table 3. Transplantation Course and Outcome
Patient
No.
Engraftment (d)
Chimerism
GVHD (Pre-DLI)
Current
Status (d)
Myeloid T Cells B Cells
ANC Platelets 3 mo 6 mo 3 mo 6 mo 3 mo 6 mo Acute* Chronic
01 12 10 N/A D N/A M N/A D Nil Nil Dead (552)
02 23 30 N/A M N/A M N/A M Nil Nil Dead (558)
03 10 12 D D D D D D Grade II (skin 3) Nil A (899)
04 12 29 D M M M D D Nil Nil A (893)
05 10 9 D D D M D D Nil Nil A (808)
06 16 20 D D M M M D Nil Nil A (783)
07 14 16 M D M M M D Nil Nil A (777)
08 14 14 D D M M D D Grade II (skin 3) Nil A (732)
09 13 11 No chimerism data available Nil Nil Dead (63)
10 11 14 FISH at 6 months—72% D Nil Nil A (693)
11 13 11 D D D M D M Nil Nil A (693)
12 12 13 No chimerism data available Grade I (skin 1) Nil A (679)
13 12 30 D M M M N/A M Nil Nil A (629)
14 11 10 D D M M D D Nil Nil A (615)
15 13 18 D D M M N/A D Grade I (skin 1) Nil Dead (303)
16 14 12 D M N/A M N/A M Grade I (skin 1) Nil Dead (467)
17 11 19 No chimerism data available Nil Nil Dead (48)
18 45 52 D D N/A M N/A M Grade I (skin 2) Limited A (300)
19 12 11 No chimerism data available Nil Nil Dead (40)
20 11 11 D M D M D M Grade II (skin 3) Nil A (234)
ANC indicates absolute neutrophil count; N/A, not available; D, donor; M, mixed; FISH, ﬂuorescent in situ hybridization; A, alive.
*Grade and stage according to consensus criteria.
Table 4. Response to Stem Cell Transplantation
Disease Status
Pretransplantation
Disease
Status after
6 mo
Best
Response
Current
Status
Complete response
(n  1)
1 Complete
response
1 Complete
response
1 Dead
Partial response
(n  18)
1 Complete
response
2 Complete
response
1 Complete
response
4 Partial
response
9 Partial
response
3 Partial
response
1 Minimal
response
1 Minimal
response
1 Minimal
response
6 No change 3 No change 2 No change
3 Progressive 3 Not
evaluable*
5 Progressive
3 Not
evaluable*
6 Dead†
Minimal response
(n  1)
1 Minimal
response
1 Partial
response
1 Progressive
*Three with early non-relapse deaths  6 mo.
†Three with early non-relapse deaths, 2 with disease progres-
sion, and 1 with disease progression and GVHD.
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attributable to the effect of alemtuzumab in reducing
the number of engraftment failures and GVHD. On
the other hand, such effective in vivo T-cell depletion
has the dual disadvantages of delaying immune recon-
stitution and potentially reducing immunological an-
titumor activity resulting in an increased relapse rate.
Indeed, infective complications contributed signiﬁ-
cantly to the early NRM despite successful treatment
of the majority of infective episodes. This pattern
probably relates both to the underlying disease and to
the markedly immunosuppressive nature of the con-
ditioning regimen.
Only 31% of evaluable patients who underwent
transplantation in the presence of residual disease
achieved a CR or PR by 6 months posttransplantation
in the present study, compared with 47% of a similar
group of chemotherapy-sensitive patients treated us-
ing a myeloablative conditioning protocol with T-cell
depletion recently reported by Alyea et al. [23]. De-
spite the antimyeloma activity offered by 140 mg/m2
melphalan, 3 patients had progressive disease by 6
months posttransplantation, and both initial cases
with adjuvant DLI planned from 12 months posttrans-
plantation had progressed prior to this. It is likely that
in vivo T-cell depletion using alemtuzumab contrib-
uted in part to early disease progression in these pa-
tients. Undoubtedly, T-cell depletion regimens carry
an increased risk of disease relapse in CML. However,
the remarkable sensitivity of CML to DLI, particu-
larly chronic-phase disease in molecular or cytoge-
netic relapse, has led to the successful use of protocols
incorporating T-cell depletion with salvage DLI early
in the course of disease relapse [24,25]. It remains
unclear whether limiting T-cell dose will compromise
the durability of remission [26] and if this type of
approach is suitable for patients with myeloma. A
proportion of cases do appear to be sensitive to the
effects of DLI [11,12]. However, current results sug-
gest that the use of DLI to treat relapsed myeloma
following allogeneic stem cell transplantation may be
limited by short duration of response and signiﬁcant
GVHD, perhaps relating partly to the high T-cell
doses required to effect these responses. Strategies
that use lower doses of DLI to prevent relapse, there-
fore, may be more successful. With such consider-
ations in mind, we designed the current study to
incorporate escalating doses of DLI to treat mixed
chimerism or persistent disease.
Disease responses were documented following
DLI in 3 of 6 patients with progressive disease and 5
Table 5. DLIs: Dose and Response
Patient
No.
Status before
DLI Donor
Donor Lymphocyte Dose*
GVHD
Best
Response
Current
Status0.1 0.3 1 3 10
01 Progression† Sibling X X X No NR Dead
02 Progression† Sibling X X No NR Dead
04 Minimal response MUD X‡ X X X Grade II PR PR
05 Minimal response MUD X X X X X No PR Prog
06 Progression Sibling X X X X X No PR Prog
07 Progression Sibling X X X X X No NC Prog
08 Partial response MUD X X No NC Prog
10 No change Sibling X X X No NC NC
11 Partial response Sibling X X‡ X Limited chronic CR Prog
12 Partial response Sibling X No NC NC
13 No change MUD X‡ X Limited chronic PR PR
14 Minimal response Sibling X X X No MR Prog
15 Progression MUD X‡ Grade IV PR Dead§
16 Progression Cousin — — X‡ Grade IV PR Dead
NR indicates no response; PR, partial response; NC, no change; CR, complete response; Prog, progression.
*107 CD3 T cells/kg.
†DLI planned from 12 mo after RIT.
‡Dose at which GVHD developed.
§Achieved PR and died from complications of chronic GVHD/infections.
Table 6. Change in Chimerism Status and T-Cell Dose
Patient
No.
Chimerism (Myeloid/T Cells/B
Cells) T-Cell Dose after
Which Chimerism
Changed (cells/kg)Pre-DLI Post-DLI
01 DMD DDD 3  106
02 MMM DMM 3  106
04 MMD DDD 1  106
05 DMD DDD 1  106
06 DMD DDD 1  106
07 DMD DDD 3  107
08 DMD DDD 1  106
11 DMM DDD 1  106
13 MMM DDD 1  106
14 DMD DDD 3  106
16 MMM MDD 1  107
10 FISH—72% D FISH—97% D 1  107
D indicates donor; M, mixed; FISH, ﬂuorescent in situ hybrid-
ization.
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of 8 patients with stable persistent disease. An addi-
tional patient with progressive disease had disease sta-
bilization for 12 months before further progression.
There appeared to be a strong correlation between
responses and the development of GVHD (P  .02).
Response rates are comparable with previously pub-
lished rates in patients with progressive disease but
lower than those reported for persistent disease (10 of
11) reported by Alyea et al. [23]. The incidence of
GVHD following DLI was higher in the study by
Alyea et al., particularly if analysis is restricted to the
sibling allograft recipients in the current study. This
may relate to the higher T-cell doses administered.
However, an association with the development of
GVHD does not appear to entirely explain differences
in response rates. Alyea et al. were able to demonstrate
some separation of GVM activity from GVHD, but,
in the current study, this was less apparent despite an
escalating-dose protocol. This difference may relate to
the use of CD8 depleted DLI by Alyea et al. In both
studies, the duration of disease response following
DLI was limited in a proportion of cases. In the
current study, 5 of 8 responses were maintained for
12 months and 2 of 8 responses were maintained for
12 months. One patient died from complications of
GVHDwith12 months follow-up having achieved a
PR.
A number of alternate approaches might reduce
the incidence of disease progression. Earlier adminis-
tration of DLI following transplantation has been re-
ported to be associated with encouraging response
rates, although GVHD resulted in signiﬁcant morbid-
ity and mortality, resulting in a change in protocol to
restrict pre-emptive DLI after the initial phase of the
study [6,7]. All responses occurred following the de-
velopment of GVHD. A de-escalation of the dose of
alemtuzumab might mediate a similar effect by allow-
ing more rapid reconstitution of immunity. Indeed,
the body of evidence for the importance of GVM
activity in allogeneic transplantation would be
strengthened if this maneuver alone were sufﬁcient to
mediate increased disease response rates by 6 months
posttransplantation. Maximizing cytoreduction with
high-dose therapy and autologous stem cell rescue
prior to allogeneic transplantation also may be bene-
ﬁcial, and this approach has been reported to combine
low NRM rates with high response rates [27]. How-
ever, the incidences of both acute and chronic GVHD
sufﬁcient to require therapy were again high (45% and
55%, respectively), and GVHD contributed signiﬁ-
cantly to NRM in this study. In addition, although the
number of cases of disease progression was low, longer
follow-up will be required given that the inclusion of
an autograft would be predicted to delay the time to
progression. Whether the development of GVHD
will prove a prerequisite for the generation of durable
responses remains to be determined.
The almost universal conversion to full donor chi-
merism in all hematopoietic lineages following DLI
illustrates the potential to separate a graft-versus-he-
matopoietic system effect from GVHD. This conver-
sion, however, was not associated with GVM activity
in all cases. In addition, even in those patients with
disease responses, subsequent disease progression oc-
curred while hematopoietic cells from all lineages in
peripheral blood samples remained entirely of donor
origin. Hence the responses directed against recipient
hematopoietic cells were insufﬁcient to control tumor
growth in all cases. The occurrence of disease pro-
gression despite persistent full donor chimerism con-
ﬁrms the results of previous smaller studies in my-
eloma, suggesting that relapse of myeloma may be due
to the development of resistance to immune destruc-
tion rather than to suppression of the immune re-
sponse [28]. The demonstration of progressive disease
without an initial response to DLI despite conversion
to tri-lineage full donor chimerism suggests either
that this resistance can already be present at the time
of DLI or that the target antigen(s) may be tumor-
speciﬁc rather than restricted to the hematopoietic
system. Further studies to delineate both the targets
and effectors of these responses, as well as the precise
mechanisms of tumor escape, will be necessary to
reduce the toxicity of this form of therapy and perhaps
to increase the durability of responses.
As in other transplantation settings, the perfect
balance of limited GVHD and optimal GVM effect is
proving difﬁcult to achieve. Although the RIT proto-
col outlined in the current study achieves low rates of
both GVHD and graft rejection, it appears that its
application in patients with myeloma may prove ex-
cessively immunosuppressive despite attempts to re-
store immune function with DLI. Although the over-
all survival rate at 24 months of 71% is encouraging
for an allogeneic protocol, the disappointing current
progression-free survival ﬁgures mitigate current ap-
plication of similar approaches in patients without
either an increased 2-microglobulin level or chro-
mosome 13 abnormality, in whom results of tandem
autologous procedures may well be superior. This
should be carefully evaluated in comparative studies.
Incorporation of an autologous transplantation proce-
dure prior to RIT may offer the dual beneﬁt of max-
imizing the extent and durability of tumor cytoreduc-
tion and allowing substantial de-escalation of the dose
of alemtuzumab resulting in more rapid reconstitution
of antitumor immunity. This will form the basis of
ongoing studies. The current study suggests that the
duration of therapeutic beneﬁt from an escalating-
dose protocol of DLI following initial T-cell deple-
tion may be limited in many cases of myeloma. At-
tempts to manipulate these responses based on a
growing understanding of the immunological targets
ultimately may be required to focus and amplify ap-
K. S. Peggs et al.
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propriate components of the allogeneic T-cell re-
sponse.
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